JT takes up cobicistat for Japan but rejigs Toray nalfurafine tie-up
This article was originally published in Scrip
Executive Summary
Japan Tobacco (JT) has acquired exclusive rights in Japan to Gilead Sciences' cobicistat, which it intends to develop and commercialise as a stand-alone booster agent for use with HIV drugs. The financial terms of the alliance were not disclosed.